Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dimeticone + nerolidol (branded as Hedrin Once Liquid Gel) is a topical combination formulation used for the treatment of head lice infestation (pediculosis capitis). Developed by Thornton & Ross, it consists of 4% dimeticone, a silicone oil, and nerolidol (Penetrol), a naturally occurring linear sesquiterpene alcohol. The mechanism of action is physical rather than neurotoxic; dimeticone acts by coating and suffocating the lice and their eggs, while nerolidol acts as a penetration enhancer and surface tension modifier to facilitate the entry of dimeticone into the breathing apparatus (spiracles) of the lice and the eggs. It is classified as a certified medical device in many jurisdictions due to its physical mode of action.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dimeticone + nerolidol.